JP2014526254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526254A5 JP2014526254A5 JP2014529994A JP2014529994A JP2014526254A5 JP 2014526254 A5 JP2014526254 A5 JP 2014526254A5 JP 2014529994 A JP2014529994 A JP 2014529994A JP 2014529994 A JP2014529994 A JP 2014529994A JP 2014526254 A5 JP2014526254 A5 JP 2014526254A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- glp
- xten
- fusion protein
- nmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 69
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 69
- 102000037865 fusion proteins Human genes 0.000 claims description 54
- 108020001507 fusion proteins Proteins 0.000 claims description 54
- 230000000968 intestinal effect Effects 0.000 claims description 41
- 230000001965 increasing effect Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 230000006378 damage Effects 0.000 claims description 24
- 230000003247 decreasing effect Effects 0.000 claims description 24
- 208000004232 Enteritis Diseases 0.000 claims description 21
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 18
- 208000002720 Malnutrition Diseases 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 18
- 238000002512 chemotherapy Methods 0.000 claims description 18
- 208000014674 injury Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 210000000813 small intestine Anatomy 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 13
- 206010061172 Gastrointestinal injury Diseases 0.000 claims description 12
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 208000037817 intestinal injury Diseases 0.000 claims description 12
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 230000001454 enterotrophic effect Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 206010012735 Diarrhoea Diseases 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 230000001228 trophic effect Effects 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000031729 Bacteremia Diseases 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 6
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 6
- 206010016946 Food allergy Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 206010059028 Gastrointestinal ischaemia Diseases 0.000 claims description 6
- 208000013016 Hypoglycemia Diseases 0.000 claims description 6
- 206010025476 Malabsorption Diseases 0.000 claims description 6
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 6
- 208000004535 Mesenteric Ischemia Diseases 0.000 claims description 6
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 6
- 201000010927 Mucositis Diseases 0.000 claims description 6
- 206010051606 Necrotising colitis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 206010033654 Pancreatitis necrotising Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001925 catabolic effect Effects 0.000 claims description 6
- 201000003146 cystitis Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 235000020932 food allergy Nutrition 0.000 claims description 6
- 230000005176 gastrointestinal motility Effects 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 235000000824 malnutrition Nutrition 0.000 claims description 6
- 230000001071 malnutrition Effects 0.000 claims description 6
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 6
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 6
- 206010034674 peritonitis Diseases 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 208000001162 steatorrhea Diseases 0.000 claims description 6
- 230000007863 steatosis Effects 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 206010044697 tropical sprue Diseases 0.000 claims description 6
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 claims description 3
- 101500025069 Bos taurus Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 3
- 101500028765 Gallus gallus Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 101500026186 Ovis aries Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 210000001100 crypt cell Anatomy 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000003886 intestinal anastomosis Effects 0.000 claims description 3
- 230000003871 intestinal function Effects 0.000 claims description 3
- -1 porcine GLP-2 Proteins 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 206010067994 Mucosal atrophy Diseases 0.000 claims description 2
- 206010062065 Perforated ulcer Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008971 epithelial apoptosis Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 230000001134 intestinotrophic effect Effects 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 241001137251 Corvidae Species 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 206010070545 Bacterial translocation Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 230000007375 bacterial translocation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 230000019439 energy homeostasis Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004678 mucosal integrity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102100032879 Glucagon-like peptide 2 receptor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 102100029693 Matrix metalloproteinase-20 Human genes 0.000 description 1
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 108090000155 pancreatic elastase II Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161573748P | 2011-09-12 | 2011-09-12 | |
| US61/573,748 | 2011-09-12 | ||
| PCT/US2012/054941 WO2013040093A2 (en) | 2011-09-12 | 2012-09-12 | Glucagon-like peptide-2 compositions and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017137310A Division JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526254A JP2014526254A (ja) | 2014-10-06 |
| JP2014526254A5 true JP2014526254A5 (enExample) | 2015-11-05 |
| JP6206972B2 JP6206972B2 (ja) | 2017-10-04 |
Family
ID=47883955
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529994A Active JP6206972B2 (ja) | 2011-09-12 | 2012-09-12 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
| JP2017137310A Pending JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017137310A Pending JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20160137711A1 (enExample) |
| EP (2) | EP3431098A1 (enExample) |
| JP (2) | JP6206972B2 (enExample) |
| KR (1) | KR102007054B1 (enExample) |
| CN (1) | CN103945861B (enExample) |
| AU (2) | AU2012308636B2 (enExample) |
| BR (1) | BR112014005744B1 (enExample) |
| CA (1) | CA2848204C (enExample) |
| DK (1) | DK2755675T3 (enExample) |
| ES (1) | ES2687651T3 (enExample) |
| PT (1) | PT2755675T (enExample) |
| WO (1) | WO2013040093A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865578C (en) | 2012-02-27 | 2023-01-17 | Amunix Operating Inc. | Xten conjugate compositions and methods of making same |
| KR20220051197A (ko) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN105602877B (zh) * | 2016-01-25 | 2019-02-01 | 广州沃德生物技术有限公司 | 一种定点改造的猪源glp-2重组植物乳杆菌及其制备方法和应用 |
| WO2018069442A1 (en) | 2016-10-12 | 2018-04-19 | University Of Copenhagen | Peptide dual agonists of gipr and glp2r |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| ES2894629T3 (es) * | 2017-06-16 | 2022-02-15 | Zealand Pharma As | Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2) |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| AU2018321841A1 (en) * | 2017-08-22 | 2020-02-20 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| ES2980055T3 (es) * | 2017-09-22 | 2024-09-27 | Kite Pharma Inc | Polipéptidos quiméricos y usos de los mismos |
| EP3689898B1 (en) * | 2017-09-28 | 2026-04-29 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative |
| CN111629745A (zh) | 2017-11-06 | 2020-09-04 | 夏尔-Nps医药品有限公司 | 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| JP2021507706A (ja) | 2017-12-21 | 2021-02-25 | アムニクス ファーマシューティカルズ， インコーポレイテッド | 放出セグメントおよびそれを含む結合組成物 |
| WO2019143193A1 (ko) * | 2018-01-19 | 2019-07-25 | 주식회사 펩진 | 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리 펩타이드를 생산하는방법 |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110305223B (zh) | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
| BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| KR20230038187A (ko) * | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| EP4222176A4 (en) | 2020-09-30 | 2024-02-28 | Beijing QL Biopharmaceutical Co., Ltd. | POLYPEPTIDE CONJUGATES AND METHODS OF USE |
| CN114213524A (zh) * | 2021-11-08 | 2022-03-22 | 苏州博领干细胞再生医学有限公司 | 用于胰高血糖素样肽-2抗体检测的包被抗原及纯化方法、重组工程菌及培养方法 |
| KR20240163717A (ko) | 2022-03-30 | 2024-11-19 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법 |
| IT202200015204A1 (it) * | 2022-07-20 | 2024-01-20 | Bioinnova S R L S | Microalghe esprimenti glp-2 e usi relativi |
| EP4593867A2 (en) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2026024863A2 (en) * | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AT387234B (de) | 1987-03-05 | 1988-12-27 | Vogelbusch Gmbh | Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| MX2007013431A (es) | 2005-05-04 | 2008-01-18 | Zealand Pharma As | Analogos del peptido 2 semejante al glucagon. |
| US20090105341A1 (en) * | 2005-12-24 | 2009-04-23 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| CN108530543B (zh) * | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| CN102741275B (zh) * | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| US20110312881A1 (en) * | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| NZ603399A (en) * | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
-
2012
- 2012-09-12 EP EP18176085.1A patent/EP3431098A1/en not_active Withdrawn
- 2012-09-12 JP JP2014529994A patent/JP6206972B2/ja active Active
- 2012-09-12 PT PT12831010T patent/PT2755675T/pt unknown
- 2012-09-12 DK DK12831010.9T patent/DK2755675T3/en active
- 2012-09-12 CA CA2848204A patent/CA2848204C/en active Active
- 2012-09-12 WO PCT/US2012/054941 patent/WO2013040093A2/en not_active Ceased
- 2012-09-12 EP EP12831010.9A patent/EP2755675B1/en active Active
- 2012-09-12 CN CN201280055552.1A patent/CN103945861B/zh active Active
- 2012-09-12 KR KR1020147009519A patent/KR102007054B1/ko active Active
- 2012-09-12 AU AU2012308636A patent/AU2012308636B2/en not_active Ceased
- 2012-09-12 BR BR112014005744-3A patent/BR112014005744B1/pt active IP Right Grant
- 2012-09-12 US US14/343,111 patent/US20160137711A1/en not_active Abandoned
- 2012-09-12 ES ES12831010T patent/ES2687651T3/es active Active
-
2017
- 2017-07-13 JP JP2017137310A patent/JP2017186374A/ja active Pending
- 2017-11-29 AU AU2017268558A patent/AU2017268558A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,125 patent/US20200392195A1/en not_active Abandoned
-
2023
- 2023-06-06 US US18/330,032 patent/US20240067695A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,005 patent/US20250388643A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3241850B1 (en) | Glp and immunoglobulin hybrid fc fused polypeptide and use thereof | |
| RU2657573C2 (ru) | Применение долгодействующих пептидов glp-1 | |
| KR102034607B1 (ko) | 글루카곤 및 glp-1 공-효능제 화합물 | |
| US8580918B2 (en) | Peptidic GLP-2 agonists | |
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| JP2025043342A (ja) | 改善されたペプチド製剤 | |
| KR102365582B1 (ko) | 인슐린 저항성에 대한 개선된 펩티드 약제 | |
| CN102292346B (zh) | 肥胖的治疗 | |
| KR20040058324A (ko) | 경비흡수용 의약 조성물 | |
| EP3670529B1 (en) | Acylated oxyntomodulin peptide analog | |
| JP2013537879A (ja) | 部位特異的ｐｅｇ修飾エキセンディン−４アナログ及びその使用 | |
| CN107206044A (zh) | 用于受控且持续释放的elp融合蛋白 | |
| JP2022551233A (ja) | 異なる構造のｇｌｐ－１アナログペプチド修飾二量体およびその調製方法のｉｉ型糖尿病の治療における用途 | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| IL323508A (en) | Methods and uses for treating nausea and vomiting | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| JP2016535015A5 (enExample) | ||
| Wang et al. | Peptide and peptide-based drugs | |
| US10105442B2 (en) | Treatment of diabetes type 1 using GLP-1 and anti-IL-21 | |
| KR20240141165A (ko) | 경구 투여를 위한 조성물들 및 방법들 | |
| MX2021011153A (es) | Peptidos para sindrome metabolico. | |
| NZ753010B2 (en) | Acylated glp-1/glp-2 dual agonists | |
| HK40032122B (zh) | 酰化胃泌酸调节素肽类似物 |